{"product_id":"global-biosimilars-follow-on-biologics-market-growth-status-and-outlook-2023-2029","title":"Global Biosimilars \u0026 Follow-on-biologics Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Biosimilars \u0026amp; Follow-on-biologics Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nLPI (LP Information)' newest research report, the “Biosimilars \u0026amp; Follow-on-biologics Industry Forecast” looks at past sales and reviews total world Biosimilars \u0026amp; Follow-on-biologics sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilars \u0026amp; Follow-on-biologics sales for 2023 through 2029. With Biosimilars \u0026amp; Follow-on-biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilars \u0026amp; Follow-on-biologics industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Biosimilars \u0026amp; Follow-on-biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilars \u0026amp; Follow-on-biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilars \u0026amp; Follow-on-biologics market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilars \u0026amp; Follow-on-biologics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilars \u0026amp; Follow-on-biologics.\u003c\/p\u003e\n\n\u003cp\u003eThe global Biosimilars \u0026amp; Follow-on-biologics market size is projected to grow from US$ 9089.2 million in 2022 to US$ 11310 million in 2029; it is expected to grow at a CAGR of 3.2% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eBiosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. \u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Biosimilars \u0026amp; Follow-on-biologics market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nHuman growth hormone\u003cbr\u003e\nErythropoietin\u003cbr\u003e\nMonoclonal antibodies\u003cbr\u003e\nInsulin\u003cbr\u003e\nInterferon\u003cbr\u003e\nGranulocyte-Colony Stimulating Factor\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nBlood Disorders\u003cbr\u003e\nOncology Diseases\u003cbr\u003e\nChronic and Autoimmune Diseases\u003cbr\u003e\nGrowth Hormone Deficiencies\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nNovartis (Sandoz)\u003cbr\u003e\nSynthon Pharmaceuticals\u003cbr\u003e\nTeva Pharmaceutical Industries\u003cbr\u003e\nLG Life Sciences\u003cbr\u003e\nCelltrion Biocon\u003cbr\u003e\nHospira\u003cbr\u003e\nMerck Serono (Merck)\u003cbr\u003e\nBiogen idec\u003cbr\u003e\nGenentech (Roche)\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 86 Pages \/ MCW16227547","offer_id":47645972005170,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-biosimilars-follow-on-biologics-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}